The Epic Collapse of Valeant Pharmaceuticals Intl Inc. Continues

Shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) have now fallen nearly 50% in the past week, prompting many investors to question if their investments are still sound.

| More on:
The Motley Fool

At this time nine months ago, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) was one of the most valuable companies in Canada.

And then the collapse started.

Shares of the embattled company dropped significantly in the months that followed as a trail of bad news and questionable practices led to investors dropping the company from their portfolios.

More news this week caused the company to drop even further to levels not seen since 2011. Here’s a quick recap of what happened and what this means for investors.

The end of the Valeant business model?

Part of how Valeant got so big so fast is due to the company’s business model. Cheap loans let Valeant scoop up drug companies that were undervalued, and then once in control Valeant would push prices up and integrate the acquired drugs into its own distribution network.

This allowed the company to bypass having its own research and development arm.

For a while, this enabled the company to grow exponentially but, as many realized, both the ballooning debt as well as the practice of raising drug prices could not last forever.

Valeant can’t pay its debts

Following a string of findings and internal reviews, Valeant announced recently that it would not seek out any more drug deals, instead opting to focus on reducing some of its massive debt.

Valeant has revised the company’s profit targets for the year–the second such downward revision in the past five months. The company also intends to delay the filing of fourth-quarter earnings as a result of improper accounting practices that were uncovered in an internal investigation.

That delay announcement also comes with a twist in that Valeant is now close to the very real possibility of defaulting on some of the $30 billion in debt it has if it is unable to file an annual report by the end of April.

CEO Michael Pearson, made note of the company’s problems in a recent conference call: “Our business is not operating on all cylinders … but we and I are committed to get it back on track.”

What’s next for investors?

Valeant’s epic collapse has cost investors billions. Pershing Square, the U.S.-based hedge fund operated by billionaire Bill Ackman, holds a significant stake in Valeant and likely lost well over a billion in just a few hours.

Despite the losses, Ackman remains committed to Valeant and intends to take a more proactive role and work to restore investor confidence.

For many investors, however, it may be too little, too late. An estimated $15 billion was erased by the recent drop in stock price.

As tempting as an investment in Valeant is given the current price, the truth is that the company is an incredibly risky investment at this point in time. In my opinion, investors would be better served by seeking out one of many other investments that offer better growth prospects.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Demetris Afxentiou has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Rocket lift off through the clouds
Tech Stocks

1 AI Stock Up 11% to Own in a TFSA for Long-Term Growth

Never mind chasing flashy AI start-ups with soaring valuations. Check out this profitable Canadian tech powerhouse that has stood the…

Read more »

A worker wears a hard hat outside a mining operation.
Metals and Mining Stocks

Ivanhoe Mines: Buy, Sell, or Hold in July 2025?

Here's what to consider before trading Ivanhoe Mines stock this month. Watch out for July 30th!

Read more »

ETF stands for Exchange Traded Fund
Investing

Earn a 4.3% Yield From Berkshire Hathaway Stock With This Monthly Income ETF

This ETF uses options and leverage to generate income from Berkshire Hathaway

Read more »

construction workers talk on the job site
Energy Stocks

This Canadian Stock Could Double Even During Market Volatility

While growth stocks ride volatility, this dependable, dividend-paying stock could double your money over time.

Read more »

A worker overlooks an oil refinery plant.
Energy Stocks

What Are Some Good Energy Stocks to Buy Now?

Cenovus Energy (TSX:CVE) and another great oil bet that could pay huge dividends.

Read more »

Forklift in a warehouse
Dividend Stocks

It’s Possible! Build a $250,000 TFSA Using Just 2 Dividend Stocks

Want a $250,000 TFSA that pays out monthly? These two solid REITs pay monthly distributions.

Read more »

Income and growth financial chart
Dividend Stocks

This Canadian Retail Stock Yields 3.8% and Keeps Expanding

A growing dividend, rising share price, and big strategic moves make this top Canadian retail stock worth owning for the…

Read more »

Senior uses a laptop computer
Retirement

How Much Can You Earn Before Losing Your Guaranteed Income Supplement?

The CRA offers the Guaranteed Income Supplement to low-income Canadians above 65. At what annual income will you lose your…

Read more »